Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia
A retrospective case series review was conducted to determine the pre-operative role and safety of pre-operative adjunctive anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab “LUCENTISTM” in patients with diabetic retinopathy requiring vitrectomy. The study involved twenty conse...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Penerbit UKM
2010
|
Online Access: | http://journalarticle.ukm.my/2086/1/08MS090_4144.pdf http://journalarticle.ukm.my/2086/ http://www.ppukm.ukm.my/ukmmcjournal/index.php |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | A retrospective case series review was conducted to determine the pre-operative role
and safety of pre-operative adjunctive anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab “LUCENTISTM” in patients with diabetic retinopathy requiring
vitrectomy. The study involved twenty consecutive eyes of sixteen patients (age range:
46-72 years; mean 57.5 years) which received intravitreal injection of 0.5 - 1 mg of
ranibizumab 3 to 8 days (mean 4.4 days) prior to vitrectomy for diabetic retinopathy.
There were no local or systemic post-injection complications. Indications for vitrectomy
were retinal detachment (RD) [n=11; 3 combined tractional (TRD) - rhegmatogenous RD
(RRD), 8 TRD], TRD with vitreous haemorrhage (VH) (n=3) ,VH (n=8) and vitreomacular
traction syndrome (n=1). Inclusion criteria include all consecutive eyes of
diabetic patients requiring vitrectomy receiving a first pre-operative injection of anti-
VEGF. Pre-operative visual acuity (VA) ranged from 6/36 to light perception. All eyes had
minimal to moderate intraoperative bleeding. Post-operative VH in eyes without
tamponade or gas tamponade was nil (n=1), mild (n=13) or moderate (n=1). Silicone
filled eyes had nil (n=1), moderate (n=3) or severe haemorrhages (n=1). Post-operative
VA was unchanged (n=2) (10%), improved (n = 14) (70%) or worsened (n=4). VA was
2/60 or better (n=15) to no light perception (n=1). Two eyes achieved 6/12 or better
vision (10%). Ten eyes (50%) had 6/36 or better vision. In conclusion, pre-operative
intravitreal ranibizumab is safe and useful in diabetic vitrectomy and appears to help with
perioperative bleeding leading to improvement in vision. |
---|